Description
Imm-1-104 is an experimental medication currently being studied in clinical trials for certain advanced or metastatic solid tumors, including colorectal cancer. It is being investigated to see if it is safe, how the body processes it, and if it has any anti-tumor activity. The trials are exploring different doses of Imm-1-104, both by itself and in combination with other standard cancer treatments. Specifically in colorectal cancer trials, Imm-1-104 is being studied in patients whose tumors have specific genetic changes (mutations) like BRAF, KRAS, or NRAS mutations. These mutations are known to affect how cancer cells grow and respond to treatment. The goal is to find the best dose and see if Imm-1-104 can help control or shrink tumors in these patients.
Mechanism of Action
Imm-1-104 is being studied as a potential treatment for cancers with RAS or MAPK pathway activation, which includes tumors with BRAF, KRAS, or NRAS mutations. The specific way Imm-1-104 works (its molecular target or mechanism) is still being investigated in clinical trials. Researchers are studying how it affects the body and its potential impact on tumor cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.